Kiora Pharmaceuticals reports Q1 net loss of $1.9M; positive clinical data for KIO-301, KIO-201, KIO-101

KIORA PHARMACEUTICALS INC

2023-Q1 EPS reported -$1.00

Net loss narrowed to $1.9M from $3.6M in Q1 2022; cash & equivalents $3.4M plus $1.7M R&D tax receivables.
KIO-301 (ABACUS trial) showed profound light perception improvements in a blind RP patient; full results by end 2023.
KIO-201 Phase 2 PCED trial met primary endpoint in 5 of 8 patients at 4 weeks; planning registration study.
KIO-101 Phase 2 OPRA trial first patient enrolled in April; targeting ocular surface disease from autoimmune conditions.
Approximately $9.6M available under equity line of credit; R&D expenses fell to $0.4M from $0.7M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

KIORA PHARMACEUTICALS INC reported first quarter ended March 31, 2023 results: net income $1.9 million.

Period: first quarter ended March 31, 2023
Net income: $1.9 million
Result: reported results

Exact text from the filing

Net loss was $1.9 million for the first quarter of 2023 compared to $3.6 million for the first quarter of 2022.

View on SEC.gov

Browse all earnings releases →

KIORA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001372514-23-000070

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.